Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Relative Risk01:12

Relative Risk

2.3K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.3K
Hazard Rate01:11

Hazard Rate

467
The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
467
Clearance Models: Noncompartmental Models01:17

Clearance Models: Noncompartmental Models

331
Clearance is a pharmacokinetic parameter traditionally defined by compartment models, signifying the rate at which a drug is expelled from the body. However, a noncompartmental model offers an alternative method for assessing clearance, primarily employing empirical data obtained after administering a single drug dose.
The noncompartmental approach capitalizes on extensive sampling data, correlating the volume of distribution to systemic exposure and the administered dosage. This method enables...
331
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

472
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
472
Hazard Ratio01:12

Hazard Ratio

670
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
670
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

677
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
677

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Guidelines and variations in patterns of GnRH analogue use in castration-resistant prostate cancer across six countries.

ESMO real world data and digital oncology·2026
Same author

Advanced risk signature analysis of inflammation markers in predicting prostate cancer using the Swedish Apolipoprotein-related MOrtality RISk (AMORIS) cohort.

ESMO real world data and digital oncology·2026
Same author

Risk of coronary stenosis after adjuvant radiotherapy for breast cancer.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2022
Same author

Primary small intestinal neuroendocrine tumors are highly prevalent and often multiple before metastatic disease develops.

Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society·2019
Same author

Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.

Breast cancer research and treatment·2018
Same author

Reply to the letter to the editor 'Age at diagnosis and prognosis among prostate cancer patients treated with radiotherapy: evidenced from three independent cohort studies' by X. Dong, G. Ma and F. Chen.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same journal

Latent Class Log-Linear Models for Estimating Diagnostic Test Accuracy Without a Gold Standard: A Simulation Study.

Statistics in medicine·2026
Same journal

Interpretable Bayesian Modeling for Multireader Multicase Studies: Addressing Overdispersion and Limited Sample Size in Diagnostic Enhancement Evaluation.

Statistics in medicine·2026
Same journal

Adaptive Sequential Multiple Hypotheses Testing for Concomitant Vaccine Safety Surveillance.

Statistics in medicine·2026
Same journal

Novel Distance Regression for Repeated Outcomes With Missing Data: Applications to Longitudinal and Crossover Studies of Microbiome Beta-Diversity.

Statistics in medicine·2026
Same journal

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same journal

Identifiable Copula-Double-Cox Models: A Fully Parametric Framework for Dependent Right-Censored Survival Data.

Statistics in medicine·2026
See all related articles

Related Experiment Video

Updated: Mar 7, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K

A latent class model for competing risks.

M Rowley1,2, H Garmo3, M Van Hemelrijck3

  • 1Institute for Mathematical and Molecular Biomedicine, King's College London, London, U.K.

Statistics in Medicine
|February 25, 2017
PubMed
Summary
This summary is machine-generated.

This study introduces a Bayesian survival analysis method to address complex data where standard assumptions fail. The approach accounts for unobserved heterogeneity, improving risk prediction and understanding disease progression.

Keywords:
competing risksheterogeneityinformative censoringsurvival analysis

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.0K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

975

Related Experiment Videos

Last Updated: Mar 7, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.0K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

975

Area of Science:

  • Biostatistics
  • Epidemiology
  • Medical Statistics

Background:

  • Survival data analysis faces challenges with violated proportional hazards assumptions and non-marginal hazard rates.
  • Unobserved cohort or disease heterogeneity can complicate survival data interpretation.
  • Existing models may not fully capture complex population structures or informative censoring.

Purpose of the Study:

  • To develop a Bayesian survival analysis method robust to violated proportional hazards and informative censoring.
  • To provide a framework for estimating risk-specific marginal hazard rates and survival functions.
  • To offer alternative explanations for counter-intuitive findings in epidemiological studies.

Main Methods:

  • A Bayesian approach assuming latent heterogeneity at the individual level.
  • Modeling that allows for proportional hazards at the individual level despite population-level violations.
  • Incorporation of techniques to 'decontaminate' survival estimates from informative censoring effects.

Main Results:

  • Simulated data confirmed the method's ability to identify cohort substructure and correct for heterogeneity-induced informative censoring.
  • Application to the Uppsala Longitudinal Study of Adult Men provided new insights into prostate cancer inferences.
  • Analysis of the Swedish Apolipoprotein Mortality Risk Study highlighted the significance of managing cardiovascular disease comorbidities in breast cancer patients.

Conclusions:

  • The proposed Bayesian method offers a flexible alternative for survival analysis when standard assumptions are not met.
  • It effectively handles unobserved heterogeneity and informative censoring, leading to more accurate survival function estimation.
  • The approach yields plausible alternative explanations for complex epidemiological findings and informs clinical management strategies.